In vitro activity of new rifamycins aganst rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria

54Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Comparisons were made of the in vitro activity of rifampicin, and the rifamycin derivatives, rifapentine, rifabutin, CGP 29861, CGP 7040 and CGP 27557, against rifampicin-sensitive and rifampicin-resistant strains of Mycobacterium tuberculosis and against the Mycobacterium avium/intracellulare/scrofulaceum (MAIS) complex. The new rifamycins had MICs four to eight times lower than those of rifampicin against sensitive M. tuberculosis strains. Of the 35 rifampicin-resistant strains of M. tuberculosis 31% were sensitive to rifabutin but only 3-11% to the other rifamycins. The proportions of the MAIS strains found to be sensitive were 35% for rifapentine and rifabutin and 85-92% for CGP 29861 and CGP 7040. © 1987.

Cite

CITATION STYLE

APA

Dickinson, J. M., & Mitchison, D. A. (1987). In vitro activity of new rifamycins aganst rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria. Tubercle, 68(3), 177–182. https://doi.org/10.1016/0041-3879(87)90053-5

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free